Trials / Completed
CompletedNCT00061594
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 426 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhuFab V2 (ranibizumab) |
Timeline
- Start date
- 2003-05-01
- Completion
- 2006-09-01
- First posted
- 2003-05-30
- Last updated
- 2014-03-19
Locations
82 sites across 6 countries: United States, Australia, Czechia, France, Germany, Hungary
Source: ClinicalTrials.gov record NCT00061594. Inclusion in this directory is not an endorsement.